Novacyt (ALNOV) - Total Assets
Based on the latest financial reports, Novacyt (ALNOV) holds total assets worth €40.28 Million EUR (≈ $47.09 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Novacyt service its debt to assess how comfortably operating cash covers total debt obligations.
Novacyt - Total Assets Trend (2008–2025)
This chart illustrates how Novacyt's total assets have evolved over time, based on quarterly financial data. See ALNOV total equity for net asset value and shareholders' equity analysis.
Novacyt - Asset Composition Analysis
Current Asset Composition (December 2025)
Novacyt's total assets of €40.28 Million consist of 68.7% current assets and 31.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 47.5% |
| Accounts Receivable | €5.01 Million | 12.4% |
| Inventory | €2.53 Million | 6.3% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €1.36 Million | 3.4% |
| Goodwill | €2.16 Million | 5.4% |
Asset Composition Trend (2008–2025)
This chart illustrates how Novacyt's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Novacyt.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Novacyt's current assets represent 68.7% of total assets in 2025, an increase from 0.0% in 2008.
- Cash Position: Cash and equivalents constituted 47.5% of total assets in 2025, up from 0.9% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, a decrease from 12.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 12.4% of total assets.
Novacyt Competitors by Total Assets
Key competitors of Novacyt based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
Germany | €2.83 Billion |
|
GN Store Nord
CO:GN
|
Denmark | Dkr29.23 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
|
Getein Biotech Inc
SHG:603387
|
China | CN¥3.70 Billion |
|
Ningbo David Medical Device Co Ltd
SHE:300314
|
China | CN¥1.45 Billion |
|
Vieworks Co. Ltd
KQ:100120
|
Korea | ₩351.89 Billion |
|
Somnomed Ltd
AU:SOM
|
Australia | AU$79.90 Million |
Novacyt - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.74 | 6.33 | 2.76 |
| Quick Ratio | 4.31 | 5.97 | 2.36 |
| Cash Ratio | 0.00 | 4.90 | 1.24 |
| Working Capital | €21.83 Million | €33.16 Million | €130.84 Million |
Novacyt - Advanced Valuation Insights
This section examines the relationship between Novacyt's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.44 |
| Latest Market Cap to Assets Ratio | 0.90 |
| Asset Growth Rate (YoY) | -43.0% |
| Total Assets | €40.28 Million |
| Market Capitalization | $36.17 Million USD |
Valuation Analysis
Near Book Valuation: The market values Novacyt's assets close to their book value (0.90x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Novacyt's assets decreased by 43.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Novacyt (2008–2025)
The table below shows the annual total assets of Novacyt from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €40.28 Million ≈ $47.09 Million |
-42.97% |
| 2024-12-31 | €70.63 Million ≈ $82.58 Million |
-47.22% |
| 2023-12-31 | €133.81 Million ≈ $156.44 Million |
-5.03% |
| 2022-12-31 | €140.90 Million ≈ $164.73 Million |
-23.30% |
| 2021-12-31 | €183.70 Million ≈ $214.76 Million |
-21.59% |
| 2020-12-31 | €234.28 Million ≈ $273.89 Million |
+782.73% |
| 2019-12-31 | €26.54 Million ≈ $31.03 Million |
-9.45% |
| 2018-12-31 | €29.31 Million ≈ $34.27 Million |
-2.96% |
| 2017-12-31 | €30.20 Million ≈ $35.31 Million |
+16.40% |
| 2016-12-31 | €25.95 Million ≈ $30.34 Million |
+105.56% |
| 2015-12-31 | €12.62 Million ≈ $14.76 Million |
-39.23% |
| 2014-12-31 | €20.77 Million ≈ $24.28 Million |
+680.10% |
| 2013-12-31 | €2.66 Million ≈ $3.11 Million |
-19.30% |
| 2012-12-31 | €3.30 Million ≈ $3.86 Million |
+162.00% |
| 2011-12-31 | €1.26 Million ≈ $1.47 Million |
-33.72% |
| 2010-12-31 | €1.90 Million ≈ $2.22 Million |
-0.94% |
| 2009-12-31 | €1.92 Million ≈ $2.24 Million |
+16.45% |
| 2008-12-31 | €1.65 Million ≈ $1.93 Million |
-- |
About Novacyt
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive h… Read more